BridgeMD
EarLy extra Measles immunisation during a measles Outbreak (ELMO)
EU CTIS ID: 2024-513395-18-00
What this study is testing
The main objective is to assess the immune response to MMR-0 immunisation given to infants younger than 12 months of age in a measles outbreak setting.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Infants eligible for an MMR-0 immunisation and willing to receive the MMR-0 immunisation or having received the MMR-0 immunisation less than 4 weeks ago (MMR-0 group only)
- Infants willing to receive the MMR-1 immunisation at 14 months of age (control group)
- Infants have to be healthy according to the same health criteria applied in the well baby clinic when a child is immunised, e.g. also children with small increases in body temperature or a cold are seen as children with normal health
- The parents/legally representatives accept participation in the study according to the described procedures
- Presence of a signed informed consent (the parents/legally representatives have given digital informed consent after receiving oral and written information)
You likely can't join if
- Having received a previous MMR immunisation (control group only)
- Confirmed measles infection before study entry
- Contra-indications as mentioned in the SmPC of the vaccine, such as expected allergy or hypersensitivity against one of the vaccine ingredients.
- Receiving immunosuppressive medication
- Known or suspected immunological disorder
- Known or suspected bleeding disorder
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.